Adicet Bio, Inc. (ACET) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -103.71M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 83.83M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-103.71M | (m) | (m) | $83.83M | (m) | (m) |
| 2026-03-31 | $-113.80M | (m) | (m) | $93.80M | (m) | (m) |
| 2025-12-31 | $-122.11M | (m) | (m) | $99.13M | (m) | (m) |
| 2025-09-30 | $-120.97M | (m) | (m) | $97.36M | (m) | (m) |
| 2025-06-30 | $-126.17M | (m) | (m) | $100.76M | (m) | (m) |
| 2025-03-31 | $-126.63M | (m) | (m) | $98.24M | (m) | (m) |
| 2024-12-31 | $-127.61M | (m) | (m) | $99.32M | (m) | (m) |
| 2024-09-30 | $-128.44M | (m) | (m) | $100.81M | (m) | (m) |
| 2024-06-30 | $-147.55M | (m) | (m) | $100.72M | (m) | (m) |
| 2024-03-31 | $-149.59M | (m) | (m) | $103.18M | (m) | (m) |
| 2023-12-31 | $-152.04M | (m) | (m) | $106.04M | (m) | (m) |
| 2023-09-30 | $-152.04M | (m) | (m) | $106.30M | (m) | (m) |
| 2023-06-30 | $-122.76M | (m) | (m) | $96.70M | (m) | (m) |
| 2023-03-31 | $-110.58M | (m) | (m) | $84.52M | (m) | (m) |
| 2022-12-31 | $-72.55M | (m) | (m) | $71.25M | (m) | (m) |
| 2022-09-30 | $-56.53M | (m) | (m) | $60.89M | (m) | (m) |
| 2022-06-30 | $-47.25M | (m) | (m) | $56.24M | (m) | (m) |
| 2022-03-31 | $-35.37M | (m) | (m) | $50.68M | (m) | (m) |
| 2021-12-31 | $-61.43M | (m) | (m) | $48.94M | (m) | (m) |
| 2021-09-30 | $-55.24M | (m) | (m) | $43.97M | (m) | (m) |
| 2021-06-30 | $-55.19M | (m) | (m) | $40.98M | (m) | (m) |
| 2021-03-31 | $-52.99M | (m) | (m) | $39.04M | (m) | (m) |
| 2020-12-31 | $-39.19M | (m) | (m) | $34.33M | (m) | (m) |
| 2020-09-30 | $-91.09M | (m) | (m) | $81.12M | (m) | (m) |
| 2020-06-30 | $-67.63M | (m) | (m) | $54.86M | (m) | (m) |
| 2020-03-31 | $-81.15M | (m) | (m) | $69.62M | (m) | (m) |
| 2019-12-31 | $-85.46M | (m) | (m) | $73.63M | (m) | (m) |
| 2019-09-30 | $-62.38M | (m) | (m) | $51.87M | (m) | (m) |
| 2019-06-30 | $-46.25M | (m) | (m) | $36.52M | (m) | (m) |
| 2019-03-31 | $-41.20M | (m) | (m) | $31.81M | (m) | (m) |
| 2018-12-31 | $-39.70M | (m) | (m) | $31.07M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-18.88M | (m) | (m) | $16.84M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |